Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration

• Status: Terminated
• Trial end date: 2011-02-01
• Target enrollment: 0
• Participant gender: Male

Summary

Aspirin has shown to be beneficial to some patients with certain diseases such as coronary artery disease or stroke. We are investigating how aspirin works on regulating platelets and thromboxane over time at different doses. We hope to find the best dose of aspirin and/or other medications to help people who are at risk for heart attack or stroke.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Vanderbilt University; Vanderbilt University Medical Center
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Males

• Age 18-40 years

• Non-smokers

Exclusion Criteria:

• ASA/NSAID use previous 14 days.

• Evidence of ASA/NSAID use within previous 14 days at baseline visit based on investigator interpretation of platelet aggregation and platelet secretion studies.

• History of chronic NSAID use.

• Currently taking NSAIDs, corticosteroids, or anticoagulants.

• History of coronary artery disease, myocardial infarction, coronary artery bypass grafting, percutaneous angioplasty, diabetes mellitus or stroke.

• History of gastric,duodenal, or esophageal ulcers or serious gastrointestinal bleed.

• History of frequent headaches, pain syndrome, or other condition requiring frequent use of analgesics.

• History of adverse reaction to ASA.

• Initial platelet count <100K/µl or >500K/µl.

• Initial hematocrit <35% or >50%.

• Weight less than 110 pounds.